Major histocompatibility complex class II binding characteristics of peptoid-peptide hybrids.

The major histocompatibility complex (MHC) class II binding requirements for solvent-exposed peptide residues were systematically studied using amino acid and peptoid substitutions. In a peptoid residue, the side chain is present on the backbone nitrogen atom as opposed to the alpha-carbon atom in an amino acid residue. To investigate the effect of this side chain shifting on MHC binding, three amino acids in the central part of the peptide sticking out of the binding groove were replaced by corresponding peptoid residues. Two peptoid-peptide hybrids showed large affinity decreases in the MHC-peptide binding assay. To investigate this affinity loss, the individual contributions to MHC binding affinity of the side chain (position), the putative hydrogen bond, and the flexibility were dissected. We conclude that the side chain position as well as the backbone nitrogen atom hydrogen bonding features of solvent-exposed residues in the peptide can be important for MHC binding affinity.

[1]  D. Wiley,et al.  The Crystal Structure of a Pyrrolinone−Peptide Hybrid Ligand Bound to the Human Class II MHC Protein HLA-DR1 , 2000 .

[2]  A. Vandenbark,et al.  Selectin of encephalitogenic rat T‐Lymphocyte clones recognizing an immunodominant epitope on myelin basic protein , 1989, Journal of neuroscience research.

[3]  R Crowther,et al.  Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. , 2000, Journal of medicinal chemistry.

[4]  S. Ceman,et al.  Individual hydrogen bonds play a critical role in MHC class II:peptide interactions: implications for the dynamic aspects of class II trafficking and DM‐mediated peptide exchange , 1999, Immunological reviews.

[5]  G. Jung,et al.  Cutting edge: N-hydroxy peptides: a new class of TCR antagonists. , 1999, Journal of immunology.

[6]  R. Campbell,et al.  Design and Synthesis of a Competent Pyrrolinone−Peptide Hybrid Ligand for the Class II Major Histocompatibility Complex Protein HLA-DR1 , 1999 .

[7]  J. Guenot,et al.  Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules , 1999, Nature Biotechnology.

[8]  P. Kourilsky,et al.  Role of peptide backbone in T cell recognition. , 1999, Journal of immunology.

[9]  Don C. Wiley,et al.  Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.

[10]  A. Sant,et al.  Cutting edge: a single, essential hydrogen bond controls the stability of peptide-MHC class II complexes. , 1999, Journal of immunology.

[11]  D. Kirschmann,et al.  A peptidomimetic that specifically inhibits human leukocyte antigen DRB1*0401-restricted T cell proliferation. , 1997, The Journal of pharmacology and experimental therapeutics.